A covalent intermediate in CD38 is responsible for ADP-ribosylation and cyclization reactions

Anthony A. Sauve, Haiteng Deng, Ruth H. Angeletti, Vern L. Schramm

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Human CD38 is an ectoenzyme expressed on the surface of B-cells that makes cyclic-ADP-ribose (cADPR) and ADP-ribose from NAD+ (nicotinamide diphosphate ribose, oxidized form). The compound cADPR is a potent second messenger for calcium release inside cells. Nicotinamide guanine dinucleotide (NGD+) is also cyclized by CD38 to form cGDPR (cyclic guanosine diphosphate ribose) and hydrolyzed to form GDPR (guanosine diphosphate ribose). Kinetic isotope effect studies in the presence of 20 mM nicotinamide gave 1'-3H and 1'-14C isotope effects of 1.02 ± 0.01 and 1.00 ± 0.01, respectively, for the cyclization reaction and 1.23 ± 0.01 and 1.02 ± 0.01, respectively, for the hydrolysis reaction. These values support a covalent intermediate. The existence of a covalent intermediate was established by reaction of ara-F-NMN+ (arabinosyl-2'-fluoro-2'-deoxynicotinamide mononucleotide) with the enzyme. This compound reacted to release 1 mol of nicotinamide/mole of CD38 monomer and to form an inactive covalent intermediate. Reaction with excess nicotinamide rescued catalytic activity with an apparent K(m) of 17 ± 5 mM and a V(max) of 0.023 ± 0.003 s-1. Proof of covalent labeling of the enzyme by this inhibitor was obtained by MS analysis. Treatment of CD38 with ara-F-NMN+ increased mass by 215 amu, consistent with formation of CD38-fluoro-sugar monophosphate. Tryptic digestion in urea, phosphatase treatment, and purification of peptides in combination with MALDI-PSD permitted identification of Glu226 as the amino acid nucleophile. This residue is highly conserved across all ADP-ribosyl (adenosine diphosphate ribosyl) cyclases. The covalent intermediate inherent to the catalytic mechanism of human CD38 provides chemical precedent for related NAD+ glycosyltransferases.

Original languageEnglish (US)
Pages (from-to)7855-7859
Number of pages5
JournalJournal of the American Chemical Society
Volume122
Issue number33
DOIs
StatePublished - Aug 23 2000

Fingerprint

Administrative data processing
Niacinamide
Cyclization
Cyclic ADP-Ribose
Adenosine Diphosphate
Isotopes
NAD
Ribose
Diphosphates
Enzymes
Adenosine Diphosphate Ribose
Glycosyltransferases
Nucleophiles
Guanosine
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Phosphatases
Second Messenger Systems
Enzyme Inhibitors
Phosphoric Monoester Hydrolases
Urea

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

A covalent intermediate in CD38 is responsible for ADP-ribosylation and cyclization reactions. / Sauve, Anthony A.; Deng, Haiteng; Angeletti, Ruth H.; Schramm, Vern L.

In: Journal of the American Chemical Society, Vol. 122, No. 33, 23.08.2000, p. 7855-7859.

Research output: Contribution to journalArticle

Sauve, Anthony A. ; Deng, Haiteng ; Angeletti, Ruth H. ; Schramm, Vern L. / A covalent intermediate in CD38 is responsible for ADP-ribosylation and cyclization reactions. In: Journal of the American Chemical Society. 2000 ; Vol. 122, No. 33. pp. 7855-7859.
@article{14c1c027dbea4bfa977e91f7af75f97a,
title = "A covalent intermediate in CD38 is responsible for ADP-ribosylation and cyclization reactions",
abstract = "Human CD38 is an ectoenzyme expressed on the surface of B-cells that makes cyclic-ADP-ribose (cADPR) and ADP-ribose from NAD+ (nicotinamide diphosphate ribose, oxidized form). The compound cADPR is a potent second messenger for calcium release inside cells. Nicotinamide guanine dinucleotide (NGD+) is also cyclized by CD38 to form cGDPR (cyclic guanosine diphosphate ribose) and hydrolyzed to form GDPR (guanosine diphosphate ribose). Kinetic isotope effect studies in the presence of 20 mM nicotinamide gave 1'-3H and 1'-14C isotope effects of 1.02 ± 0.01 and 1.00 ± 0.01, respectively, for the cyclization reaction and 1.23 ± 0.01 and 1.02 ± 0.01, respectively, for the hydrolysis reaction. These values support a covalent intermediate. The existence of a covalent intermediate was established by reaction of ara-F-NMN+ (arabinosyl-2'-fluoro-2'-deoxynicotinamide mononucleotide) with the enzyme. This compound reacted to release 1 mol of nicotinamide/mole of CD38 monomer and to form an inactive covalent intermediate. Reaction with excess nicotinamide rescued catalytic activity with an apparent K(m) of 17 ± 5 mM and a V(max) of 0.023 ± 0.003 s-1. Proof of covalent labeling of the enzyme by this inhibitor was obtained by MS analysis. Treatment of CD38 with ara-F-NMN+ increased mass by 215 amu, consistent with formation of CD38-fluoro-sugar monophosphate. Tryptic digestion in urea, phosphatase treatment, and purification of peptides in combination with MALDI-PSD permitted identification of Glu226 as the amino acid nucleophile. This residue is highly conserved across all ADP-ribosyl (adenosine diphosphate ribosyl) cyclases. The covalent intermediate inherent to the catalytic mechanism of human CD38 provides chemical precedent for related NAD+ glycosyltransferases.",
author = "Sauve, {Anthony A.} and Haiteng Deng and Angeletti, {Ruth H.} and Schramm, {Vern L.}",
year = "2000",
month = "8",
day = "23",
doi = "10.1021/ja001139c",
language = "English (US)",
volume = "122",
pages = "7855--7859",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "33",

}

TY - JOUR

T1 - A covalent intermediate in CD38 is responsible for ADP-ribosylation and cyclization reactions

AU - Sauve, Anthony A.

AU - Deng, Haiteng

AU - Angeletti, Ruth H.

AU - Schramm, Vern L.

PY - 2000/8/23

Y1 - 2000/8/23

N2 - Human CD38 is an ectoenzyme expressed on the surface of B-cells that makes cyclic-ADP-ribose (cADPR) and ADP-ribose from NAD+ (nicotinamide diphosphate ribose, oxidized form). The compound cADPR is a potent second messenger for calcium release inside cells. Nicotinamide guanine dinucleotide (NGD+) is also cyclized by CD38 to form cGDPR (cyclic guanosine diphosphate ribose) and hydrolyzed to form GDPR (guanosine diphosphate ribose). Kinetic isotope effect studies in the presence of 20 mM nicotinamide gave 1'-3H and 1'-14C isotope effects of 1.02 ± 0.01 and 1.00 ± 0.01, respectively, for the cyclization reaction and 1.23 ± 0.01 and 1.02 ± 0.01, respectively, for the hydrolysis reaction. These values support a covalent intermediate. The existence of a covalent intermediate was established by reaction of ara-F-NMN+ (arabinosyl-2'-fluoro-2'-deoxynicotinamide mononucleotide) with the enzyme. This compound reacted to release 1 mol of nicotinamide/mole of CD38 monomer and to form an inactive covalent intermediate. Reaction with excess nicotinamide rescued catalytic activity with an apparent K(m) of 17 ± 5 mM and a V(max) of 0.023 ± 0.003 s-1. Proof of covalent labeling of the enzyme by this inhibitor was obtained by MS analysis. Treatment of CD38 with ara-F-NMN+ increased mass by 215 amu, consistent with formation of CD38-fluoro-sugar monophosphate. Tryptic digestion in urea, phosphatase treatment, and purification of peptides in combination with MALDI-PSD permitted identification of Glu226 as the amino acid nucleophile. This residue is highly conserved across all ADP-ribosyl (adenosine diphosphate ribosyl) cyclases. The covalent intermediate inherent to the catalytic mechanism of human CD38 provides chemical precedent for related NAD+ glycosyltransferases.

AB - Human CD38 is an ectoenzyme expressed on the surface of B-cells that makes cyclic-ADP-ribose (cADPR) and ADP-ribose from NAD+ (nicotinamide diphosphate ribose, oxidized form). The compound cADPR is a potent second messenger for calcium release inside cells. Nicotinamide guanine dinucleotide (NGD+) is also cyclized by CD38 to form cGDPR (cyclic guanosine diphosphate ribose) and hydrolyzed to form GDPR (guanosine diphosphate ribose). Kinetic isotope effect studies in the presence of 20 mM nicotinamide gave 1'-3H and 1'-14C isotope effects of 1.02 ± 0.01 and 1.00 ± 0.01, respectively, for the cyclization reaction and 1.23 ± 0.01 and 1.02 ± 0.01, respectively, for the hydrolysis reaction. These values support a covalent intermediate. The existence of a covalent intermediate was established by reaction of ara-F-NMN+ (arabinosyl-2'-fluoro-2'-deoxynicotinamide mononucleotide) with the enzyme. This compound reacted to release 1 mol of nicotinamide/mole of CD38 monomer and to form an inactive covalent intermediate. Reaction with excess nicotinamide rescued catalytic activity with an apparent K(m) of 17 ± 5 mM and a V(max) of 0.023 ± 0.003 s-1. Proof of covalent labeling of the enzyme by this inhibitor was obtained by MS analysis. Treatment of CD38 with ara-F-NMN+ increased mass by 215 amu, consistent with formation of CD38-fluoro-sugar monophosphate. Tryptic digestion in urea, phosphatase treatment, and purification of peptides in combination with MALDI-PSD permitted identification of Glu226 as the amino acid nucleophile. This residue is highly conserved across all ADP-ribosyl (adenosine diphosphate ribosyl) cyclases. The covalent intermediate inherent to the catalytic mechanism of human CD38 provides chemical precedent for related NAD+ glycosyltransferases.

UR - http://www.scopus.com/inward/record.url?scp=0034706050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034706050&partnerID=8YFLogxK

U2 - 10.1021/ja001139c

DO - 10.1021/ja001139c

M3 - Article

VL - 122

SP - 7855

EP - 7859

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 33

ER -